Speaker Profile

Ph.D., Associate Professor Microbiology and Immunology, Investigator PICI, UCSF; Co-Founder, Arsenal Bio

Biography
Dr. Roybal is an Associate Professor in the Department of Microbiology and Immunology at the UCSF. He is a member of the Parker Institute for Cancer Immunotherapy and an inaugural Chan Zuckerberg Biohub Investigator. He was recently awarded the Sartorius and Science Magazine Prize for Regenerative Medicine and Cell Therapy and the NIH New Innovator Award. The Roybal lab harnesses the tools of synthetic biology to engineer to control and enhance engineered immune cell therapies. His body of work was foundational to the next-generation immune cell therapy company, Cell Design Labs, where he was a founding scientist (now part of Gilead). He was also instrumental in developing universal CAR T cell technology in collaboration with Xyphos Biosciences (now part of Astellas). He has recently co-founded Arsenal Biosciences, which focuses on building cellular therapies for solid tumors with a combination of cutting-edge synthetic biology and gene editing technologies.

Talk
Development of NextGen Cellular Therapeutics with Synthetic Biology
Engineered immune cell therapies for cancer suffer from life-threatening toxicities or inefficacy depending on the clinical indication. I will provide an overview of our synthetic biology toolkit that allows for the control and customization of immune cell responses to improve the safety and efficacy of cell-based therapies.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chair:
Ira Mellman, Genentech

Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance

    Sessions:
  • Recent Advances in Cell-based Therapy
    Session Chair: Ira Mellman, Genentech
    - Nicholas Haining, ArsenalBio
    - Elliot Norry, Adaptimmune
    - Sarah Cooley, Fate Therapeutics
    - Liz Homans, Lyell
  • Patentability of Immunotherapies - Latest Developments
    - Janet Xiao, Morrison & Foerster LLP
  • Cell-based Therapy Challenges
    Session Chair: Lawrence Corey, Fred Hutchinson Cancer Research Center
    - Sharon Benzeno, Adaptive Biotechnologies
    - Arati Rao, PACT Pharma
    - Mark Kotter, bit.bio
  • Next-generation Supply Chain For Cell & Gene Therapies
    Session Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Amy DuRoss, Vineti
    - Tim Moore, Pact Pharma
    - Teresa Foy, BMS
  • Biomarkers to Guide Immunotherapy
    Session Chair: Danny Wells, ImmunAI
    - Sanjeev Mariathasan, Genentech
    - Christine Spencer, PICI
    - Klaus Lindpaintner, InterVenn Bioscience
  • Advances in Multi-Omic Spatial Profiling
    Session Chair: Sarah Warren, NanoString Technologies
    - Chris Corless, OHSU
  • Engineered Therapeutics
    Session Chair: Daniel Chen, SITC
    - Kole Roybal, UCSF
    - Paul Parren, Lava Therapeutics